Publication | Closed Access
Overlapping and distinct biological effects of IL-6 classic and trans-signaling in vascular endothelial cells
57
Citations
49
References
2021
Year
ImmunologyImmune RegulationCell DeathCcl2 ExpressionVascular Endothelial CellsInflammationAngiogenesisDistinct Biological EffectsHuman EcsCell SignalingMolecular SignalingEndothelial Cell PathobiologyAutoimmune DiseaseInflammatory PropertiesChronic InflammationAutoimmunityVascular BiologyPharmacologyCell BiologyCytokineSignal TransductionEndothelial DysfunctionMedicine
IL-6 affects tissue protective/reparative and inflammatory properties of vascular endothelial cells (ECs). This cytokine can signal to cells through classic and trans-signaling mechanisms, which are differentiated based on the expression of IL-6 receptor (IL-6R) on the surface of target cells. The biological effects of these IL-6-signaling mechanisms are distinct and have implications for vascular pathologies. We have directly compared IL-6 classic and trans-signaling in ECs. Human ECs expressed IL-6R in culture and in situ in coronary arteries from heart transplants. Stimulation of human ECs with IL-6, to model classic signaling, triggered the activation of phosphatidylinositol 3-kinase (PI3K)-Akt and ERK1/2 signaling pathways, whereas stimulation with IL-6 + sIL-6R, to model trans-signaling, triggered activation of STAT3, PI3K-Akt, and ERK1/2 pathways. IL-6 classic signaling reduced persistent injury of ECs in an allograft model of vascular rejection and inhibited cell death induced by growth factor withdrawal. When inflammatory effects were examined, IL-6 classic signaling did not induce ICAM or CCL2 expression but was sufficient to induce secretion of CXCL8 and support transmigration of neutrophil-like cells. IL-6 trans-signaling induced all inflammatory effects studied. Our findings show that IL-6 classic and trans-signaling have overlapping but distinct properties in controlling EC survival and inflammatory activation. This has implications for understanding the effects of IL-6 receptor-blocking therapies as well as for vascular responses in inflammatory and immune conditions.
| Year | Citations | |
|---|---|---|
Page 1
Page 1